DR. ALLEN ROBERT RADIN, M.D.
Osteopathic Medicine at 81 St, New York, NY
License number
New York 137910
Category
Osteopathic Medicine
Type
Rheumatology
Address
Address
50 E 81St St SUITE 1, New York, NY 10028
Phone
(212) 289-6855
(212) 584-9573 (Fax)
(212) 584-9573 (Fax)
Professional information
Executive Director At Regeneron Pharmaceuticals
Position:
Executive Director, Translational Medicine at Regeneron Pharmaceuticals
Location:
Greater New York City Area
Industry:
Biotechnology
Work:
Regeneron Pharmaceuticals
since Jan 2011
-
Executive Director, Translational Medicine
Regeneron Pharmaceuticals
Jan 2006 - Dec 2010
-
Senior Director, Translational Medicine
Regeneron Pharmaceuticals
Apr 2004 - Dec 2005
-
Director, Clinical Sciences, Immunology
Abbott Laboratories
Dec 2000 - Mar 2004
-
Associate Director, Immunosciences
Education:
New York University School of Medicine
MD
MD
Allen Radin, New York NY
Specialties:
Internist, Rheumatologist
Address:
50 East 81St Suite 1, New York, NY 10128
Education:
Medical School - NYU Graduated 1977
SUNY at Stony Brook Graduated 1978 (Internship)
SUNY at Stony Brook Graduated 1980 (Residency)
NYU Medical Center Graduated 1982 (Fellowship)
SUNY at Stony Brook Graduated 1978 (Internship)
SUNY at Stony Brook Graduated 1980 (Residency)
NYU Medical Center Graduated 1982 (Fellowship)
Languages:
English
Professional Memberships:
Fellow American College of Physicians, Fellow Americqan College of Rheumatology, NYS Medical Society, NY County Medical Society
Board certifications:
American Board of Internal Medicine, Rheumatology (Internal Medicine)
Hospital affiliations:
Lenox Hill Hospital
Methods For Treating Atopic Dermatitis By Administering An Il-4R Antagonist
US Patent:
2014007, Mar 13, 2014
Filed:
Sep 4, 2013
Appl. No.:
14/017333
Inventors:
Neil GRAHAM - Croton-on-Hudson NY, US
Jennifer Davidson HAMILTON - Hopewell Junction NY, US
Stephane C. KIRKESSELI - Paris, FR
Sudeep KUNDU - New York NY, US
Jeffrey MING - Bridgewater NJ, US
Allen RADIN - New York NY, US
Ross E. ROCKLIN - Basking Ridge NJ, US
Steven Paul WEINSTEIN - Hartsdale NY, US
Jennifer Davidson HAMILTON - Hopewell Junction NY, US
Stephane C. KIRKESSELI - Paris, FR
Sudeep KUNDU - New York NY, US
Jeffrey MING - Bridgewater NJ, US
Allen RADIN - New York NY, US
Ross E. ROCKLIN - Basking Ridge NJ, US
Steven Paul WEINSTEIN - Hartsdale NY, US
Assignee:
Regeneron Pharmaceuticals, Inc. - Tarrytown NY
International Classification:
A61K 39/395, A61K 31/58, A61K 31/573, A61K 45/06, C07K 16/28
US Classification:
4241721
Abstract:
The present invention provides methods for treating atopic dermatitis (AD). Also provided are methods for improving one or more AD-associated parameter(s), and methods for decreasing the level of at least one AD-associated biomarker in a subject in need thereof. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody.
Dr. Allen R Radin, New York NY - MD (Doctor of Medicine)
Specialties:
Rheumatology
Address:
50 E 81St St STE 1, New York 10028
(212) 289-6855 (Phone), (212) 584-9573 (Fax)
(212) 289-6855 (Phone), (212) 584-9573 (Fax)
Certifications:
Internal Medicine, 1980, Rheumatology, 1982
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
New York University School Of Medicine
Graduated: 1977
SUNY Stony Brook Hosps
Graduated: 1978
Graduated: 1980
New York University
Graduated: 1982
New York University School Of Medicine
Graduated: 1977
SUNY Stony Brook Hosps
Graduated: 1978
Graduated: 1980
New York University
Graduated: 1982
Method Of Treating Rheumatoid Arthritis With An Il-6R Antibody
US Patent:
2010031, Dec 16, 2010
Filed:
May 14, 2010
Appl. No.:
12/780006
Inventors:
Allen Radin - New York NY, US
Sean Stevens - San Diego CA, US
Tammy T. Huang - Goldens Bridge NY, US
Joel H. Martin - Putnam Valley NY, US
Jeanette L. Fairhurst - White Plains NY, US
Ashique Rafique - Yonkers NY, US
Eric Smith - New York NY, US
Kevin J. Pobursky - Beacon NY, US
Nicholas J. Papadopoulos - LaGrangeville NY, US
James P. Fandl - LaGrangeville NY, US
Gang Chen - Yorktown Heights NY, US
Margaret Karow - Camarillo CA, US
Sean Stevens - San Diego CA, US
Tammy T. Huang - Goldens Bridge NY, US
Joel H. Martin - Putnam Valley NY, US
Jeanette L. Fairhurst - White Plains NY, US
Ashique Rafique - Yonkers NY, US
Eric Smith - New York NY, US
Kevin J. Pobursky - Beacon NY, US
Nicholas J. Papadopoulos - LaGrangeville NY, US
James P. Fandl - LaGrangeville NY, US
Gang Chen - Yorktown Heights NY, US
Margaret Karow - Camarillo CA, US
Assignee:
Regeneron Pharmaceuticals, Inc. - Tarrytown NY
International Classification:
A61K 39/395, A61P 19/02, A61P 29/00
US Classification:
4241331, 4241301, 4241581, 4241421
Abstract:
The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.
Methods Of Using Il-1 Antagonists To Reduce C-Reactive Protein
US Patent:
2006017, Aug 3, 2006
Filed:
Feb 2, 2006
Appl. No.:
11/346007
Inventors:
Steven Weinstein - Hartsdale NY, US
Margaret Karow - Putnam Valley NY, US
Allen Radin - New York NY, US
William Roberts - Scarsdale NY, US
Li-Hsien Wang - Somers NY, US
Scott Mellis - New Rochelle NY, US
Margaret Karow - Putnam Valley NY, US
Allen Radin - New York NY, US
William Roberts - Scarsdale NY, US
Li-Hsien Wang - Somers NY, US
Scott Mellis - New Rochelle NY, US
International Classification:
A61K 39/395, A61K 38/17
US Classification:
424145100, 514012000
Abstract:
Methods of reducing C-reactive protein (CRP) in a subject, comprising administering to the subject a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein CRP is reduced. The IL-1 antagonist is preferably an IL-1-binding fusion protein (IL-1 trap), preferably comprising SEQ ID NO:2.
Methods Of Using Il-1 Antagonists To Treat Polymyalgia Rheumatica And Giant Cell Arteritis
US Patent:
2006016, Jul 20, 2006
Filed:
Jan 13, 2006
Appl. No.:
11/332434
Inventors:
Allen Radin - New York NY, US
Catherine Vicary - New York NY, US
Joanne Papadopoulos - LaGrangeville NY, US
Catherine Vicary - New York NY, US
Joanne Papadopoulos - LaGrangeville NY, US
International Classification:
A61K 38/17
US Classification:
514012000
Abstract:
Methods of treating, inhibiting, or ameliorating polymyalgia rheumatica (PMR) and/or giant cell arteritis (GCA) in an adult or juvenile human subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein PMR and/or GCA are inhibited, or ameliorated. The IL-1 antagonist is an IL-1 antagonist (“trap”), preferably comprising a sequence selected from the group consisting of SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, or a substantially identical having at least 95% identity to the sequence shown in SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 and capable of binding and inhibiting IL-1.
Use Of An Il-1 Antagonist For Treating Arthritis
US Patent:
7361350, Apr 22, 2008
Filed:
Feb 11, 2005
Appl. No.:
11/056730
Inventors:
Scott Mellis - New Rochelle NY, US
Neil Stahl - Carmel NY, US
Allen Radin - New York NY, US
Steven Weinstein - Hartsdale NY, US
Denise Calaprice - Nyack NY, US
Margaret Karow - Putnam Valley NY, US
Joanne Papadopoulos - LaGrangeville NY, US
Neil Stahl - Carmel NY, US
Allen Radin - New York NY, US
Steven Weinstein - Hartsdale NY, US
Denise Calaprice - Nyack NY, US
Margaret Karow - Putnam Valley NY, US
Joanne Papadopoulos - LaGrangeville NY, US
Assignee:
Regeneron Pharmaceuticals, Inc. - Tarrytown NY
International Classification:
A61K 39/00, C07K 14/715
US Classification:
4241851, 4241921, 514 12, 530350
Abstract:
Methods of treating, inhibiting, or ameliorating arthritis, including rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, or juvenile rheumatoid arthritis, in a human subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein arthritis inhibited, or ameliorated. The IL-1 antagonist is an IL-1-specific fusion protein comprising an IL-1 binding portion of the extracellular domain of human II-1RAcP, an IL-1 binding portion of the extracellular domain of human IL-1RI, and a multimerizing component antagonist, preferably comprising a sequence selected from the group consisting of SEQ ID NO:4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, or a substantially identical sequence.
Method Of Treating Rheumatoid Arthritis With An Anti-Il-6R Antibody
US Patent:
8568721, Oct 29, 2013
Filed:
May 3, 2012
Appl. No.:
13/462938
Inventors:
Allen Radin - New York NY, US
Sean Stevens - San Francisco CA, US
Tammy T. Huang - Goldens Bridge NY, US
Joel H. Martin - Putnam Valley NY, US
Jeanette L. Fairhurst - White Plains NY, US
Ashique Rafique - Yonkers NY, US
Eric Smith - New York NY, US
Kevin J. Pobursky - Beacon NY, US
Nicholas J. Papadopoulos - LaGrangeville NY, US
James P. Fandl - LaGrangeville NY, US
Gang Chen - Yorktown Heights NY, US
Margaret Karow - Santa Rosa Valley CA, US
Sean Stevens - San Francisco CA, US
Tammy T. Huang - Goldens Bridge NY, US
Joel H. Martin - Putnam Valley NY, US
Jeanette L. Fairhurst - White Plains NY, US
Ashique Rafique - Yonkers NY, US
Eric Smith - New York NY, US
Kevin J. Pobursky - Beacon NY, US
Nicholas J. Papadopoulos - LaGrangeville NY, US
James P. Fandl - LaGrangeville NY, US
Gang Chen - Yorktown Heights NY, US
Margaret Karow - Santa Rosa Valley CA, US
Assignee:
Regeneron Pharmaceuticals, Inc. - Tarrytown NY
International Classification:
A61K 39/395
US Classification:
4241431, 4241301, 4241411, 4241421, 4241441
Abstract:
The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.
Method Of Treating Rheumatoid Arthritis With An Anti-Il-6R Antibody
US Patent:
8192741, Jun 5, 2012
Filed:
Nov 1, 2011
Appl. No.:
13/286261
Inventors:
Allen Radin - New York NY, US
Sean Stevens - San Francisco CA, US
Tammy T. Huang - Goldens Bridge NY, US
Joel H. Martin - Putnam Valley NY, US
Jeanette L. Fairhurst - White Plains NY, US
Ashique Rafique - Yonkers NY, US
Eric Smith - New York NY, US
Kevin J. Pobursky - Beacon NY, US
Nicholas J. Papadopoulos - LaGrangeville NY, US
James P. Fandl - LaGrangeville NY, US
Gang Chen - Yorktown Heights NY, US
Margaret Karow - Santa Rosa Valley CA, US
Sean Stevens - San Francisco CA, US
Tammy T. Huang - Goldens Bridge NY, US
Joel H. Martin - Putnam Valley NY, US
Jeanette L. Fairhurst - White Plains NY, US
Ashique Rafique - Yonkers NY, US
Eric Smith - New York NY, US
Kevin J. Pobursky - Beacon NY, US
Nicholas J. Papadopoulos - LaGrangeville NY, US
James P. Fandl - LaGrangeville NY, US
Gang Chen - Yorktown Heights NY, US
Margaret Karow - Santa Rosa Valley CA, US
Assignee:
Regeneron Pharmaceuticals, Inc. - Tarrytown NY
International Classification:
A61K 39/395
US Classification:
4241431, 4241301, 4241411, 4241421, 4241441, 514885
Abstract:
The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.